Tenax Financial Statements From 2010 to 2026

TENX Stock  USD 11.75  0.63  5.09%   
Tenax Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tenax Therapeutics' valuation are provided below:
Market Capitalization
72.7 M
Earnings Share
(0.74)
We have found one hundred twenty available fundamental trend indicators for Tenax Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tenax Therapeutics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 89.3 M in 2026, despite the fact that Enterprise Value is likely to grow to (348.7 K).

Tenax Therapeutics Total Revenue

0.0

Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 78.2 K, Other Operating Expenses of 23.5 M or Research Development of 15.3 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 1.12. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Tenax Stock
Check out the analysis of Tenax Therapeutics Correlation against competitors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Tenax Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets116.7 M111.2 M41.5 M
Slightly volatile
Short and Long Term Debt Total359.5 K576 K384 K
Very volatile
Other Current Liabilities1.2 M1.8 M1.7 M
Slightly volatile
Total Current Liabilities5.7 M5.4 M3.3 M
Pretty Stable
Accounts Payable3.8 M3.6 M1.3 M
Slightly volatile
Cash114.5 M109.1 M29.5 M
Slightly volatile
Cash And Short Term Investments114.5 M109.1 M31.1 M
Slightly volatile
Common Stock Shares Outstanding18.4 M17.6 MM
Slightly volatile
Liabilities And Stockholders Equity116.7 M111.2 M41.5 M
Slightly volatile
Other Current Assets2.2 M2.1 M811 K
Slightly volatile
Other Stockholder Equity491.3 M467.9 M255.7 M
Slightly volatile
Total LiabilitiesM5.4 M4.6 M
Slightly volatile
Total Current Assets116.7 M111.2 M32 M
Slightly volatile
Short Term Debt604.8 K576 K308.4 K
Slightly volatile
Common Stock25.6527.019.7 K
Slightly volatile
Common Stock Total Equity1.1 K1.1 K26.7 K
Slightly volatile
Property Plant Equipment172.3 K265.3 K171.8 K
Very volatile
Current Deferred Revenue1.091.15344.5 K
Slightly volatile
Capital Surpluse226.5 M288.2 M216.7 M
Slightly volatile
Other Liabilities9.6 M9.2 M6.3 M
Slightly volatile
Non Current Liabilities Other46.2 K69.4 K56.2 K
Slightly volatile
Short and Long Term Debt372.4 K576 K318.2 K
Slightly volatile
Net Invested Capital111.1 M105.8 M24.4 M
Slightly volatile
Net Working Capital111.1 M105.8 M23.5 M
Slightly volatile
Long Term Debt Total99.3 K111.7 K122 K
Slightly volatile

Tenax Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization78.2 K41.4 K79.2 K
Slightly volatile
Other Operating Expenses23.5 M22.4 M16.4 M
Pretty Stable
Research Development15.3 M14.6 M8.7 M
Slightly volatile
Total Operating Expenses23.5 M22.4 M16.3 M
Pretty Stable
Selling General AdministrativeM7.8 M6.9 M
Pretty Stable
Selling And Marketing Expenses6.5 K6.8 K93.1 K
Slightly volatile
Interest Income2.3 M2.2 M606.3 K
Slightly volatile

Tenax Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11.8 M11.3 M8.4 M
Very volatile
Other Non Cash Items25.1 K26.4 K5.4 M
Pretty Stable
Total Cash From Financing Activities120.6 M114.9 M31.5 M
Slightly volatile
End Period Cash Flow114.5 M109.1 M29.3 M
Slightly volatile
Stock Based Compensation1.4 M1.3 M264.6 K
Slightly volatile
Change To Netincome26.7 M25.4 M11.9 M
Slightly volatile
Issuance Of Capital Stock7.9 M10.6 M8.6 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield3.313.724.0649
Slightly volatile
Days Sales Outstanding431421416
Pretty Stable
Average Payables2.5 M2.4 M1.1 M
Slightly volatile
Capex To Depreciation0.02240.02360.4078
Slightly volatile
Inventory Turnover0.831.21.2828
Very volatile
Days Of Inventory On Hand299315480
Slightly volatile
Average Inventory242.9 K150.5 K138.8 K
Slightly volatile
Cash Per Share6.797.147.7 K
Slightly volatile
Income Quality0.540.760.6844
Slightly volatile
Intangibles To Total Assets0.430.410.4351
Pretty Stable
Current Ratio19.4718.546.5517
Slightly volatile
Receivables Turnover1.721.151.0986
Very volatile
Capex Per Share0.140.15359
Slightly volatile
Average Receivables27.4 K28.8 K75.8 K
Slightly volatile
Interest Debt Per Share0.00160.00179.2 K
Slightly volatile
Debt To Assets0.04680.04930.0996
Slightly volatile
Operating Cycle400421664
Slightly volatile
Ebt Per Ebit1.711.041.0878
Very volatile
Quick Ratio19.4718.546.5418
Slightly volatile
Net Income Per E B T0.990.970.8965
Slightly volatile
Cash Ratio19.118.195.358
Slightly volatile
Days Of Inventory Outstanding299315480
Slightly volatile
Days Of Sales Outstanding431421416
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.151.0242
Slightly volatile
Debt Ratio0.04680.04930.0996
Slightly volatile
Gross Profit Margin0.760.720.7458
Slightly volatile

Tenax Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap89.3 M85.1 M43.1 M
Pretty Stable

Tenax Fundamental Market Drivers

Forward Price Earnings0.299
Cash And Short Term Investments94.9 M

Tenax Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.15  1.09 
Cost Of Revenue8.7 K8.3 K
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 130.94  137.49 
Research And Ddevelopement To Revenue 121.62  127.70 
Capex To Revenue 2.00  2.10 
Revenue Per Share 0.63  0.60 
Ebit Per Revenue(364.89)(346.65)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.